Innova Partnerships Launches Commercialisation Hub in South East England
Jan 07, 2016
To mark their 10th year of operations, Innova Partnerships Ltd is starting 2016 with the appointment of a new Business Development Director and the opening of a new commercialisation hub in South East England.
Innova Partnerships Ltd builds and grows life science enterprises through partnering, investment and a range of commercialisation services.
The company has appointed Dr Paul Meakin as Director of Business Development. Paul has a strong background in commercialisation and sales with companies such as Forsite Diagnostics and most recently worked with Knowledge Transfer Network in the agri-tech and early-stage investment teams.
He will head up Innova Partnerships’ presence in strategically important markets including London, Cambridge and Oxford. These will be served from a new location in Bedford.
Entering their 10th year, Innova Partnerships Ltd have made this move in response to increased demand and a growing customer base in these regions.
Innova CEO Prof Steve Howell is currently visiting professor of King’s College London and the company has a broad client base operating in key life science clusters such as Oxford and Cambridge. Innova Partnerships Ltd also drove formation and commercialisation of Reminova Ltd, a dental spin out from King’s College London in 2014.
Steve commented, “We are excited to build upon our presence in a region that is important in shaping global life sciences and aligned to the work we undertake at Innova Partnerships. We look forward to working with Paul to build a heightened presence and becoming embedded in the local life science ecosystems of South East England".
Biotangents; Primed for Success
- Oct 19, 2017
Dr Andrew McNair Appointed as Innova Partnerships Managing Director
- Jul 21, 2017
Innova Partnerships Exits Portfolio Company: Innova Biosciences Acquired by SYGNIS AG
- Jun 21, 2017
Portfolio Company, Relaymed, Signs Strategic Alliance with Siemens Healthineers to Seamlessly Deliver Point-of-Care Test Results to HER Systems
- May 18, 2017
Portfolio Company, Innova Biosciences, valued at €12.8 Million to be Acquired by Sygnis AG
- May 08, 2017